« Return to News | Technology Solutions

DiaryPRO helps Insys Therapeutics with data efficacy

Wednesday, February 15, 2012 03:28 PM

DiaryPRO, invivodata’s field-based electronic COA solution, captured the primary efficacy data in the pivotal studies that led to Insys Therapeutics’ successful New Drug Application (NDA) for Subsys (fentanyl sublingual spray).

Since Insys needed to demonstrate the onset of pain relief following medication, it chose an electronic diary (eDiary) to capture this critical patient reported outcome (PRO) data.  Insys selected invivodata’s DiaryPRO for its phase III clinical trial based on its effectiveness at capturing real-time, patient-centered data and user-friendly features that enable patients to easily record data, even during temporary, and sometimes severe, pain flares. 

“We had a very good experience working with invivodata and are thrilled with the results they delivered in support of the Subsys development program,” said Neha Parikh, senior director of clinical operations at Insys. “We feel strongly that without invivodata’s expertise in designing and implementing effective COA data capture solutions, we could not have captured the critical, time-sensitive data we needed to demonstrate the full therapeutic benefit of Subsys.”

Share:          
CWWeekly

May 21

Parexel consultant testifies on FDA biosimilars guidance

Global Telecom Testing checks ex-U.S. toll-free phone lines for multinational clinical trials

To read the full articles for this issue of CWWeekly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

CWWeekly

May

Newer sites most optimistic about the future
Investigative sites of all sizes, from part-time physician-run sites to large dedicated research centers, report a rebound in operating conditions, according to a new CenterWatch analysis, yet sites from each subgroup indicate they have concerns…

Risk-based monitoring slow to catch on with industry
It's estimated that the cost of physically sending monitors to all investigative sites at regular intervals, a model the industry itself developed and has adhered to for about a decade, eats up one-third to one-half of…

Eye On Millennium
Millennium, The Takeda Oncology Company, discovers and develops novel treatments applying world-class recombinant technology to a wide variety of oncology disease targets…

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

Already a digital subscriber? Access this issue now.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

Copyright © 1995-2012 CenterWatch.